Slide Codrix Lab review: two descriptions imply different application roles

Slide Codrix Lab is used by two websites whose product roles differ. A screen for reviewing information and an account capable of placing trades need different permissions and responsibilities. The shared wording does not establish that both sites supply one application.

What the available sources show

The modelexorex-100.com presentation, captured on 21 September 2026, advertises funding from INR 21,000 and AI-assisted trading. The modelexorex100.net about page emphasizes decision support, reviewable information and avoiding personalized financial advice. No common ownership or unified agreement was authenticated. Neither description was tested through a login, and the funding figure is not a verified price for both domains.

Reading the claim carefully

From a user-interface perspective, permission to view an insight is different from permission to place an order. A demo showing readable prompts would not establish the latter. We would need the specific account flow and provider documentation before treating the two descriptions as one usable journey.

Conditions and conclusion

Ask which product you would access and whether it only displays information or also submits instructions. Match its publisher, contracting company and any payment recipient. If execution is offered, request the permission limits and a method to stop new instructions without confusing that action with closing existing positions. Those controls have not been verified. The verdict remains unknown, with no app installation, trading test or withdrawal result. Combining both pages would create a richer feature list than the evidence supports; a recommendation needs the specific application and its actual terms.